BioCorRx (BICX) AI Stock Analysis

• Market Cap: $8.12M
• Dividend Yield: N/A
• Average Volume (3M): 600.00
• Price to Earnings (P/E): ―
• Beta (1Y): 0.34
• Revenue Growth: -91.40%
• EPS Growth: -8.98%
• Country: US
• Employees: 3
• Sector: Healthcare
• Sector Strength: 38
• Industry: Medical - Care Facilities
• EPS (TTM): -0.14
• Shares Outstanding: 16,996,851
• 10 Day Avg. Volume: 850
• 30 Day Avg. Volume: 600
• PEG Ratio: -0.08
• Price to Book (P/B): -0.49
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.47
• Enterprise Value/Market Cap: 1.13
• Enterprise Value/Revenue: 2.53
• Enterprise Value/Gross Profit: 9.01
• Enterprise Value/Ebitda: -1.25
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 28 Underperform
• Price Target: ―

BioCorRx's overall stock score is significantly impacted by its weak financial performance, characterized by declining revenues, high leverage, and negative cash flows. Technical analysis provides a slight positive note with signs of potential upward momentum, but the valuation remains a major concern due to negative profitability metrics. The absence of earnings call data and corporate events further emphasizes the need for a strategic turnaround.

BioCorRx Business Overview & Revenue Model

Company Description

BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition. The company is also developing BICX101, an injectable naltrexone product; and BICX104, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California.

How the Company Makes Money

BioCorRx Inc. generates revenue through the sale of its addiction treatment products, particularly its naltrexone implant, which is distributed to healthcare providers and clinics specializing in addiction treatment. The company also makes money by offering a comprehensive recovery program that includes counseling and support services, which can be sold directly to treatment centers or licensed as a package. Additionally, BioCorRx may engage in partnerships with medical facilities and practitioners to expand the reach of its programs and products, contributing to its revenue streams.

BioCorRx Financial Statement Overview

Summary

BioCorRx is facing significant financial challenges, with declining revenues, consistent losses, high leverage, and negative cash flows. The company's financial health is weak, indicating an urgent need for a strategic turnaround to improve its financial position.

Income Statement

BioCorRx's revenue has declined significantly from 2020 to 2024, with a noticeable drop in 2024. Both EBIT and EBITDA margins are deeply negative, indicating operational inefficiencies and financial distress. Net profit margins are also negative, showing consistent losses over the years.

Balance Sheet

The company has a negative stockholders' equity, which is concerning. The debt-to-equity ratio is not meaningful due to negative equity, and the equity ratio is negative, indicating liabilities exceed assets significantly. This highlights a high leverage risk and financial instability.

Cash Flow

Operating cash flow is negative, showing the company is not generating enough cash from operations. Free cash flow is also negative, although there was an improvement in financing cash flow. The free cash flow to net income ratio is unfavorable, pointing to poor cash conversion from net income.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	7.67K	89.16K	213.84K	48.27K	122.62K
Gross Profit	6.00K	53.17K	198.56K	42.39K	26.67K
EBITDA	-3.59M	-2.68M	-3.15M	-4.48M	-2.83M
Net Income	-5.11M	-3.77M	-4.37M	-5.80M	-4.01M
Balance Sheet
Total Assets	385.94K	388.89K	766.59K	819.98K	1.83M
Cash, Cash Equivalents and Short-Term Investments	88.03K	65.22K	68.61K	85.84K	592.05K
Total Debt	2.81M	1.81M	1.68M	1.65M	955.59K
Total Liabilities	12.74M	10.34M	8.97M	7.78M	6.04M
Stockholders Equity	-12.12M	-9.82M	-8.08M	-6.84M	-4.09M
Cash Flow
Free Cash Flow	-1.10M	-1.85M	-2.04M	-3.59M	-2.16M
Operating Cash Flow	-1.10M	-1.85M	-2.04M	-3.54M	-2.15M
Investing Cash Flow	0.00	0.00	0.00	-50.00K	-9.23K
Financing Cash Flow	1.12M	1.85M	2.02M	3.08M	107.30K

BioCorRx Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.48
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BICX, the sentiment is Positive. The current price of 0.48 is above the 20-day moving average (MA) of 0.40, above the 50-day MA of 0.37, and above the 200-day MA of 0.37, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 66.17 is Neutral, neither overbought nor oversold. The STOCH value of 67.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BICX.

BioCorRx Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AMS	70 Outperform	$16.13M	11.35	6.16%	―	35.25%	175.21%
TOI	54 Neutral	$342.84M	―	-227.77%	―	17.64%	13.86%
Sector *	51 Neutral	$7.35B	0.50	-65.61%	2.47%	15.28%	1.44%
CCEL	49 Neutral	$39.96M	380.00	93.38%	8.06%	1.10%	98.13%
CMPS	47 Neutral	$407.10M	―	-71.30%	―	―	3.88%
CCM	40 Underperform	$26.05M	―	14.03%	―	-29.82%	-2.57%
BICX	28 Underperform	$8.12M	―	41.50%	―	-91.40%	-8.98%